

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 14, 2023

Mind Medicine (MindMed) Inc.

(Exact name of Registrant as Specified in Its Charter)

New York
(State or Other Jurisdiction
of Incorporation)

001-40360
(Commission File Number)

98-1582438
(IRS Employer
Identification No.)

**One World Trade Center
Suite 8500
New York, New York**
(Address of Principal Executive Offices)

10007
(Zip Code)

Registrant's Telephone Number, Including Area Code: (212) 220-6633

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|----------------------------|------------------------------|--|
| Common Shares | MNMD | The Nasdaq Stock Market LLC |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01 Regulation FD Disclosure.

On August 14, 2023, Mind Medicine (MindMed) Inc. (the “Company”) posted an updated corporate presentation on the Company’s website, which the Company may use from time to time in conversations with investors, analysts or other third parties.

In accordance with General Instruction B.2. of Form 8-K, the information in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

Item 8.01 Other Events.

As disclosed above, on August 14, 2023, the Company updated its corporate presentation, which is attached as Exhibit 99.1 hereto. The information in Exhibit 99.1 is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

| Exhibit No. | Description |
|--------------------|---|
| 99.1 | Investor presentation dated August 14, 2023 |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MIND MEDICINE (MINDMED) INC.

Date: August 14, 2023

By: /s/ Robert Barrow
Name: Robert Barrow
Title: Chief Executive Officer


img158589805_0.jpg



img158589805_1.jpg




img158589805_2.jpg



There is an Urgent Need for Better Treatments

Substantial opportunities exist to advance novel treatments for a wide range of brain health disorders



1 in 4 U.S. Adults has a Diagnosable Mental Health Disorder ¹

GAD

10%

1-year prevalence of anxiety disorders in the US ¹

ADHD

4.4%

estimated prevalence rate of ADHD among all US adults ²

ASD


\$461B

economic cost of ASD in the US predicted by 2025 ³

1. Mental and Substance Use Disorders Prevalence Study (MDPSU): Findings Report 2023
2. Kessler RC, Adler L, Barkley R, et al. 2005; *Am J Psychiatry*, 163(4).
3. Leigh & Du 2015; *J Autism Dev Disord*, 45(12).

Research & Development Pipeline

Our pipeline diversification offers potential opportunities across therapeutic areas and mechanisms of action



* Continued development of MM-110 is currently subject to the Company obtaining non-dilutive sources of capital and/or collaboration partners.

** Full trial details and clinical trial links available at mindmed.co/clinical-trials/


ADHD: Attention-Deficit/Hyperactivity Disorder; LSD: lysergic acid diethylamide; MDMA: 3,4-methylenedioxymethamphetamine

Advancing the Field with Strong IP & Strategic Competitive Moats

MindMed seeks to protect innovation and market potential through intellectual property-oriented R&D strategies



Strategic Life Cycle Management & Late-Stage IP Development Can Significantly Extend Market Protection



*For illustrative purposes only
R&D: Research & Development; LCM: Life Cycle Management; NCE: New Chemical Entity

MM-120

LSD D-tartrate


Key Milestones Anticipated

Phase 2b in GAD
Topline Data | Q4 2023

Phase 2a in ADHD
Topline Data | Q4 2023 / Q1 2024

Lead Candidate with Evidence Across Multiple Therapeutic Areas


Extensive evidence of clinical benefit and mechanistic rationale in psychiatry and other brain disorders¹



1. Gasser 2016, J. Nerv. Ment. Dis., 202(7).
2. Fuentes 2020, Front Psychiatry, 10:943.


Emerging Treatment Paradigm for Brain Health Disorders

MM-120 is a potent serotonin agonist with potential applications to a broad range of brain health disorders ¹




Mechanism of Action Driving Potential Durable Clinical Response


Unique mechanism of action increases brain connectivity, enabling rapid and durable effects



img158589805_10.jpg



img158589805_11.jpg



img158589805_12.jpg



img158589805_13.jpg



img158589805_14.jpg




img158589805_15.jpg



img158589805_16.jpg



img158589805_17.jpg



img158589805_18.jpg



img158589805_19.jpg



img158589805_20.jpg



img158589805_21.jpg



Preclinical Data Indicate Potential Enhanced Benefit/Risk Profile


Preclinical data suggest the R-enantiomer of MDMA has prosocial effects with reduced stimulant activity

Translational preclinical data suggest that R(-)-MDMA may have:

- Strong prosocial effects
- Less stimulant activity compared to MDMA
- Plan to develop standard, at-home dose regimen

Source: [1][2]

R(-)-MDMA Maintains Prosocial Effects with Reduced Stimulant Activity



Source: [2]

1. Pitts 2018; Psychopharmacology, 235.
2. Curry 2018; Neuropharmacology, 128.


Clinical Data Support Opportunity for MDMA in ASD

Pilot clinical trial results of MDMA demonstrate acute and durable positive effects on social functioning in ASD population¹

MM-402 or R(-)-MDMA is a pharmaceutically optimized enantiomer of MDMA

- Potential first-in-class therapy for core symptoms of ASD
- Pilot clinical data suggest racemic MDMA could enhance social functioning
- Pharmacological profile aligns with patient-desired treatment benefits

MDMA Reduces Social Anxiety in ASD



Source: [1]

1. Danforth 2018, Psychopharmacology; 335.
MDMA: 3,4-methylenedioxymethamphetamine; ASD: Autism Spectrum Disorder

Collaborations & Early R&D

External Collaborations Aim to Accelerate Discovery & Development

Leveraging key partnerships and collaborations with intent to accelerate drug discovery and de-risk clinical development

MindShift
Compounds

Universitätsspital
Basel

NEW CHEMICAL ENTITY DISCOVERY ENGINE

ADVANCED DRUG DELIVERY

EFFICIENT CLINICAL PROVING GROUND



DISCOVERY &
LEAD OPTIMIZATION



NOVEL DOSAGE AND DELIVERY FORMS
TO ENABLE ENHANCED DELIVERY



RAPID DATA GENERATION &
CLINICAL CONCEPT TESTING

Exclusive Collaboration with Leading Researchers

MindMed's exclusive collaboration with the Liechti Lab at UHB enables efficient evidence generation to support R&D strategy



Our Leadership Team

Our management has decades of successful leadership, product development, and commercialization in pharma and biopharma



Robert Barrow
Chief Executive Officer and Board Director



Miri Halperin Wernli, PhD
Executive President



Daniel Karlin, MD, MA
Chief Medical Officer



Schond Greenway, MBA
Chief Financial Officer



Mark Sullivan, JD
Chief Legal Officer and Corporate Secretary



Francois Lienthal, MD, MBA
Chief Commercial Officer




Carrie Liao, CPA
Chief Accounting Officer



OLATEC



Morgan Stanley



Our R&D Leadership Team

Our R&D team has decades of successful leadership, product development, and commercialization in pharma and biopharma




Peter Mack, PhD
VP, Pharmaceutical Development



Bridget Walton, MS, RAC
VP, Global Regulatory Affairs



Robert Silva, PhD
VP, Head of Development



Carole Abel, MBA
VP, Programs & Portfolio Office (PPO)



Our Team Has Significant Drug Development Experience

Our Management and R&D team's relevant experience overseeing the approval of drug candidates positions MindMed for success

CNS Products

Rozerem
ramelteon 8 mg tablets

Stalevo
(carbidopa, levodopa and entacapone) tablets

Trintellix
vortioxetine
5mg-10mg-20mg tablets

Lamictal
lamotrigine tablets

Suboxone Sublingual
(buprenorphine and naloxone) $\text{\textcircled{C}}$ Film
2 mg/2 mg • 4 mg/4 mg • 8 mg/8 mg • 12 mg/12 mg

Fintepla
(fenturamine) $\text{\textcircled{C}}$
2.2 mg/mL oral solution

Selincro
nalmefene

Sublocade
(buprenorphine extended-release)
injection for subcutaneous use $\text{\textcircled{C}}$
100mg-300mg

Latuda
(lurasidone HCl) tablets

TEMBEXA
brincicofovir
33 mg/mL oral suspension | 100 mg tablets

Other Products

Pifeltro
darifenacin 120 mg tablets

BREZTRI
BRETENNEP
Bretazenone 400 mg, 600 mg, 800 mg tablets
Bretazenone 400 mg, 600 mg, 800 mg tablets

Tivicoy
(salsalate) tablets
10 mg | 25 mg | 50 mg

ZEPATIER
ezetimibe/ergosterol tablets

Traclead
125 mg

Viread
tenofovir disoproxil fumarate

Delstrigo
Elvitegravir, Cobicistat, Emtricitabine, and Raltegravir tablets

Relenza
zanamivir tablets

Ventavis
(iloprost) INHALATION SOLUTION

NOXAFIL
posaconazole

Upravi
Saxipipag
tablets 200 mg

VICTRELIS
boceprevir, MSD

ZADITOR
Systeme
ZADITOR

ISENTRESS
raltegravir
film-coated tablets 400 mg

REYATAZ
(atazanavir) 125 mg/125 mg tablets

ZOSTAVAX
valacyclovir tablets 500 mg

PREZISTA
(darunavir) tablets

Dovato
dolutegravir 50 mg/ lamivudine 300 mg tablets

Business Highlights

- A leader in developing psychedelic product candidates to treat brain health disorders
- Diversified pipeline of clinical programs targeting significant unmet medical needs
- IP and R&D strategies intended to maximize market exclusivity and protection
- Leveraging decades of research on clinical and preclinical potential of product candidates
- Expertise in drug and digital medicine development and commercialization
- Expected cash runway through key clinical readouts and into 2026¹
- **MM-120 (LSD D-tartrate)** for the treatment of GAD and ADHD
 - Phase 2b dose-optimization study ongoing for the treatment of GAD; topline results expected in Q4 2023
 - Phase 2a study ongoing for the treatment of ADHD; topline results expected in Q4 2023 / Q1 2024
- **MM-402 or R(-)-MDMA** for the treatment of core symptoms of ASD
 - IND-enabling studies ongoing; initiation of a Phase 1 clinical trial is planned in Q4 2023
 - Phase 1 (UHB) investigator-initiated trial of R-, S- and R/S-MDMA in healthy volunteers ongoing; topline results expected H1 2024

1. The company's ending Q2 2023 cash and cash equivalents of \$116.9 million and committed credit facility are expected to fund operations into 2026, if certain milestones are achieved that unlock additional capital.



